Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Further developments at Lilly in the area of glutamate receptor potentiation

March 10, 2000

Dexanabinol effective in preclinical MS model

March 10, 2000

Neurocrine initiates first in a series of clinical trials for insomnia treatment

March 10, 2000

Esters providing sustained release of MDL-100907 prepared at Aventis

March 9, 2000

Dexanabinol successfully completes phase II trials

March 9, 2000

NeoTherapeutics' nerve regeneration platform receives further patent protection

March 8, 2000

MetaPhore targets pain as the first indication for lead SOD mimetic

March 8, 2000

NIAID researchers describe antiscrapie compounds with promising activity in preclinical models

March 8, 2000

Warner-Lambert patents reduced dipeptide N-type Ca2+ channel blockers

March 8, 2000

Calcium antagonists and glutamate release inhibitors in development at Eisai

March 8, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...